VolitionRx Ltd. Files 2024 Annual Report

Ticker: VNRX · Form: 10-K · Filed: Mar 31, 2025 · CIK: 93314

Sentiment: neutral

Topics: annual-report, financials, diagnostics

TL;DR

VNRX 10-K filed: FY24 results out, check for subsequent events.

AI Summary

VolitionRx Ltd. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its business operations and financial condition. The company, formerly known as Standard Capital Corp, is involved in diagnostic substances and is headquartered in Henderson, Nevada. The filing details its fiscal year-end results and includes various subsequent events and disclosures.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of VolitionRx's financial performance and strategic positioning for the past fiscal year.

Risk Assessment

Risk Level: medium — The company operates in the highly regulated and competitive biotechnology sector, which carries inherent risks.

Key Numbers

Key Players & Entities

FAQ

What were VolitionRx's total revenues for the fiscal year ending December 31, 2024?

The filing indicates total revenues of $81,898,321 for the fiscal year ending December 31, 2024.

What was VolitionRx's net income for the fiscal year ending December 31, 2024?

VolitionRx reported a net income of $96,097,485 for the fiscal year ending December 31, 2024.

When was VolitionRx Ltd. formerly known as?

VolitionRx Ltd. was formerly known as STANDARD CAPITAL CORP, with a date of name change on August 12, 1999.

What is the primary business address for VolitionRx Ltd.?

The primary business address is 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON, NV 89014.

What are some of the subsequent events disclosed in the filing?

The filing lists several subsequent events, including those dated March 24, 2025, January 1, 2025, March 17, 2025, March 7, 2025, February 26, 2025, and January 15, 2025.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding VOLITIONRX LTD (VNRX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing